Introduction
Prostate adenocarcinoma is the most common malignant neoplasm of the prostate gland, accounting for over 95% of all prostate cancers. It arises from the glandular epithelial cells of the prostate, a walnut-sized organ located below the bladder and anterior to the rectum, responsible for producing seminal fluid.
Globally, it is the second most frequently diagnosed cancer in men and a leading cause of cancer-related mortality. While many prostate adenocarcinomas are indolent (slow-growing) and may never cause harm during a man’s lifetime, a significant subset exhibits aggressive biology, necessitating timely intervention. Understanding the spectrum of this disease—from microscopic pathology to systemic metastatic spread—is critical for informed decision-making regarding screening, diagnosis, and management.
Epidemiology and Risk Factors
Incidence and Prevalence
Prostate cancer demonstrates marked geographical and ethnic variation.
- High Incidence: North America, Northern/Western Europe, Australia, and the Caribbean.
- Low Incidence: Asia, Northern Africa.
- Age: Rare before age 40; incidence rises exponentially after 50. The median age at diagnosis is approximately 66 years.
- Lifetime Risk: Approximately 1 in 8 men will be diagnosed during their lifetime.
Established Risk Factors
| Risk Factor | Relative Risk / Association | Notes |
|---|---|---|
| Advancing Age | Strongest risk factor | Exponential increase after 50; rare < 40. |
| Race / Ethnicity | Black men: ~1.7x higher incidence; ~2.1x higher mortality vs. White men. Asian men: Lowest rates. | Disparities driven by genetics, access to care, tumor biology, and social determinants of health. |
| Family History | 2–3x risk with 1 first-degree relative (father/brother). Higher if diagnosed < 60 or multiple relatives affected. | Suggests hereditary component; ~5–10% of cases are strictly hereditary. |
| Genetic Mutations | BRCA2: High penetrance, aggressive disease. BRCA1, HOXB13, ATM, CHEK2, MSH2/MLH1 (Lynch syndrome). | Germline testing recommended for metastatic, high-risk localized, or strong family history. |
| Geography/Environment | Migration studies show risk adopts host country rates within 1–2 generations. | Implicates diet, lifestyle, and environmental exposures. |
Modifiable & Suspected Risk Factors
| Factor | Link with prostate cancer |
|---|---|
| Diet | Processed red meat and high-fat dairy may raise risk; tomatoes (lycopene), cruciferous vegetables and soy may protect. Evidence is mixed. |
| Obesity | Little effect on overall risk, but linked to aggressive, advanced and recurrent disease. |
| Smoking | Higher death rate and more aggressive tumours. |
| Chemicals | Agent Orange; firefighting exposure (IARC Group 1). |
| Vasectomy | Large studies show no meaningful link. |
Pathophysiology and Molecular Biology
Zonal Origin
The prostate is divided into anatomical zones. ~70–75% of adenocarcinomas arise in the Peripheral Zone (PZ), posteriorly, making them palpable on Digital Rectal Exam (DRE). ~15–20% arise in the Transition Zone (TZ), often associated with Benign Prostatic Hyperplasia (BPH). The Central Zone (CZ) accounts for < 5%.
Molecular Pathways
Prostate adenocarcinoma is genomically heterogeneous. Key alterations include:
| Pathway | What happens | Why it matters |
|---|---|---|
| Androgen receptor (AR) | Main growth signal for prostate cells. | Basis of hormone therapy. |
| TMPRSS2-ERG fusion | Androgen-driven ERG overexpression; about 50% of cases. | Common early event. |
| PTEN loss | Activates PI3K/AKT; 30–40% of localised cancers. | Linked to aggressive disease. |
| TP53 / RB1 loss | Late events. | Treatment resistance, neuroendocrine change. |
| DNA repair defects | BRCA2, BRCA1, ATM, PALB2, CHEK2 mutations. | Eligibility for PARP inhibitors. |
| MSI-H / dMMR | About 3–5% of metastatic cases. | May respond to immunotherapy. |
Histological Classification: “How Does It Look”
This section details the microscopic appearance (histopathology), imaging characteristics, and gross morphology of prostate adenocarcinoma.
1. Gross Pathology (Macroscopic Appearance)
| Feature | Appearance |
|---|---|
| Typical tumour | Firm, yellow-tan, gritty, poorly defined nodule; unlike rubbery, well-defined BPH nodules. |
| Location | Mostly the posterior peripheral zone, felt on rectal exam. |
| Capsule breach | Bulge through the capsule suggests pT3a. |
| Seminal vesicle invasion | Hardening of the vesicle wall (pT3b). |
| Rare variants | Cystic, haemorrhagic or diffusely infiltrating. |
2. Microscopic Pathology (Histology) – The Gleason Grading System
Diagnosis is confirmed via core needle biopsy (systematic ± MRI-targeted) or radical prostatectomy specimen. The gold standard for grading is the Gleason Score (GS), modified by the 2014 International Society of Urological Pathology (ISUP) consensus, now reported as Grade Groups (GG).
Architectural Patterns (Gleason Patterns 1–5)
- Pattern 3 (Well-differentiated): Discrete, well-formed glands of varying size/shape, infiltrating benign stroma. Most common pattern.
- Pattern 4 (Poorly differentiated): Fused glands, cribriform (sieve-like), glomeruloid, or poorly formed glands. Cribriform pattern 4 carries worse prognosis.
- Pattern 5 (Undifferentiated): Solid sheets, cords, or single cells (no lumen formation). Comedonecrosis (central necrosis) is a feature of Pattern 5.
Scoring & Grade Groups
The Gleason Score = Primary (most common) Pattern + Secondary (2nd most common) Pattern.
- Tertiary Pattern: A minor high-grade component (e.g., Pattern 5 in a 3+4=7 tumor) upgrades the score.
| Grade Group | Gleason Score | Pattern Composition | Clinical Significance |
|---|---|---|---|
| GG 1 | 3 + 3 = 6 | Only Pattern 3 | Low Risk. Very low metastatic potential. Eligible for Active Surveillance. |
| GG 2 | 3 + 4 = 7 | Mostly Pattern 3, minor Pattern 4 | Favorable Intermediate. Pattern 4 % < 5% or 5–10% is prognostic. |
| GG 3 | 4 + 3 = 7 | Mostly Pattern 4, minor Pattern 3 | Unfavorable Intermediate. Higher risk of extraprostatic extension. |
| GG 4 | 4 + 4 = 8 3 + 5 = 8 5 + 3 = 8 |
Predominantly Pattern 4 or Pattern 5 component | High Risk. Significant risk of seminal vesicle invasion, lymph node spread. |
| GG 5 | 4 + 5 = 9 5 + 4 = 9 5 + 5 = 10 |
Any Pattern 5 component | Very High Risk. Aggressive biology, high metastatic potential. |
Critical Note: Pure Gleason 3+3=6 (GG1) lacks the molecular hallmarks of metastatic competence (rarely harbors PTEN loss or TP53 mutation). This biological reality underpins Active Surveillance protocols.
3. Histological Variants (WHO Classification)
While Acinar Adenocarcinoma (Conventional) is the vast majority (>95%), recognition of variants alters prognosis and management:
| Variant | Key features | Behaviour and treatment |
|---|---|---|
| Ductal | Tall columnar cells, papillary/cribriform pattern; PSA often low. | Advanced at diagnosis; less hormone-responsive. |
| Mucinous | Pools of mucin outside cells. | Rare; aggressive. |
| Signet ring cell | Mucin pushes the nucleus aside. | Very aggressive. |
| Small cell / neuroendocrine | Synaptophysin, chromogranin, CD56 positive; AR and PSA negative; no Gleason grade. | Platinum chemotherapy, as for small cell lung cancer. |
| Sarcomatoid | Mixed epithelial and spindle-cell areas. | Very rare; poor outlook. |
4. Immunohistochemistry (IHC) – Diagnostic Adjuncts
Used on biopsy when morphology is ambiguous (e.g., Atypical Small Acinar Proliferation – ASAP).
- Basal Cell Markers (Negative in Cancer): p63, CK5/6 (CK903), HMWCK (34βE12). Benign glands have a basal layer; cancer lacks it.
- AMACR (P504S / Racemase): Positive in ~80-90% of cancers. Overexpressed in malignant epithelium. Also positive in High-Grade PIN (HGPIN).
- NKX3.1: Highly sensitive/specific nuclear marker for prostatic origin (useful in metastatic workup).
- PSA / PSAP: Confirm prostatic differentiation (less specific for malignancy vs. benign).
5. Precursor Lesions
- High-Grade Prostatic Intraepithelial Neoplasia (HGPIN): Architecturally benign glands with cytologically malignant nuclei. Risk factor for subsequent cancer diagnosis on repeat biopsy (~15-30%), but not cancer itself. Does not elevate PSA.
- Atypical Small Acinar Proliferation (ASAP): “Suspicious but not diagnostic.” Mandates repeat biopsy.
6. Radiological Appearance (“How It Looks on Imaging”)
Multiparametric MRI (mpMRI) – PI-RADS v2.1
The standard for detection, localization, and staging.
| Sequence | Cancer Appearance (Peripheral Zone) | Cancer Appearance (Transition Zone) |
|---|---|---|
| T2-Weighted (T2W) | Hypointense (Dark) nodule/region vs. bright normal PZ stroma. Ill-defined margins. | Lenticular/Non-circumscribed hypointense mass. Circumscribed = likely BPH nodule. |
| Diffusion Weighted (DWI/ADC) | Restricted Diffusion: High signal on high b-value (b=1400/2000); Low ADC values (dark on ADC map). | Restricted Diffusion is primary determinant for PI-RADS score in TZ. |
| Dynamic Contrast Enhanced (DCE) | Early, rapid enhancement (“wash-in”) and often “wash-out”. | Secondary; upgrades PI-RADS 3 to 4 if positive. |
PI-RADS Assessment Categories:
| PI-RADS score | Likelihood of significant cancer |
|---|---|
| 1 | Very low |
| 2 | Low |
| 3 | Equivocal |
| 4 | High |
| 5 | Very high |
PSMA PET/CT (Prostate-Specific Membrane Antigen)
- Indication: Staging high-risk localized disease (replacing CT/Bone scan); Biochemical Recurrence (BCR) post-treatment.
- Appearance: Intense focal uptake (SUVmax often > 10-20) in primary tumor, lymph nodes, bone, or visceral sites. Superior sensitivity/specificity vs. conventional imaging for low PSA values (< 0.5 ng/mL).
Bone Scan (Tc-99m MDP)
- Appearance: “Hot spots” (increased osteoblastic activity). Prostate cancer is predominantly osteoblastic (bone-forming).
- “Super Scan”: Diffusely increased skeletal uptake with absent renal/bladder activity = widespread metastatic burden.
- Flare Phenomenon: Transient worsening on scan 3-6 months after starting effective therapy (sign of healing/response), not progression.
Clinical Presentation: Symptoms
Crucial Concept: Early, localized prostate adenocarcinoma is almost universally asymptomatic. Symptoms typically arise from local progression
(obstruction/invasion), metastatic spread, or comorbid BPH (which coexists frequently). Attributing urinary symptoms to cancer without evaluation can delay diagnosis of treatable BPH or miss high-risk cancer in asymptomatic men.
1. Lower Urinary Tract Symptoms (LUTS) – “Obstructive/Storage”
Caused by urethral compression from an enlarging tumor (usually Transition Zone) or coexisting BPH.
- Storage: Frequency, urgency, nocturia (waking >1-2x/night), urge incontinence.
- Voiding: Hesitancy, weak/intermittent stream, straining, terminal dribbling, sensation of incomplete emptying.
- Post-Voiding: Post-micturition dribble.
Clinical Pearl: LUTS severity correlates poorly with cancer stage/grade. Many men with high-grade cancer have zero symptoms; many with severe LUTS have only BPH.
2. Locally Advanced Disease Symptoms (T3/T4)
Tumor extends beyond the capsule.
| Symptom | Cause |
|---|---|
| Blood in urine | Invasion of urethra or bladder neck. |
| Blood in semen | Seminal vesicle invasion. |
| Urinary retention | Blocked bladder outlet; may need a catheter. |
| Infections, stones, kidney swelling | Long-standing obstruction; can lead to kidney failure. |
| Rectal or perineal pain | Invasion of the rectum or nerves (T4). |
3. Metastatic Disease Symptoms (M1)
| Problem | Typical features | Action |
|---|---|---|
| Bone pain | Spine, pelvis, ribs, femur; deep ache, worse at night. Bone is affected in 85–90% of metastatic cases. | Pain relief, radiotherapy, bone-targeted drugs. |
| Spinal cord compression | Back pain, leg weakness, numbness, bladder or bowel problems. | Emergency: MRI spine, dexamethasone, radiotherapy or surgery within 24 hours. |
| Fractures | Hip or vertebrae after minimal injury. | Orthopaedic care. |
| Lymph nodes | Painless nodes or blocked ureters. | Imaging, stenting if needed. |
| Visceral spread | Liver, lung, rarely brain; usually late disease. | Systemic treatment. |
| General symptoms | Fatigue, anaemia, weight loss. | Supportive care. |
4. Symptoms Related to Treatment (Iatrogenic)
Not disease symptoms, but critical for patient counseling.
- ADT (Androgen Deprivation Therapy): Hot flashes, loss of libido, erectile dysfunction, gynecomastia, muscle loss, osteopenia/fractures, metabolic syndrome (insulin resistance, dyslipidemia), cognitive changes, depression.
- Surgery (RP): Stress urinary incontinence (SUI), erectile dysfunction (ED), penile shortening, climacturia (urine leak with orgasm), anastomotic stricture.
- Radiation (EBRT/Brachytherapy): Radiation cystitis (urgency, frequency, hematuria), proctitis (rectal urgency, bleeding, mucus), fatigue, secondary malignancy risk (long term >10 yrs).
Diagnostic Pathway
1. Screening & Early Detection
| Tool | What it shows | Limitations / notes |
|---|---|---|
| PSA blood test | Prostate-specific, not cancer-specific; age-adjusted ranges (e.g. under 2.5 ng/mL at 40–49). | Raised by BPH, prostatitis, retention, ejaculation, cycling. A rise over 0.75 ng/mL per year is a warning sign. |
| Digital rectal exam | Nodule, hardness or asymmetry in the peripheral zone. | Clinical stage: T2a half a lobe or less, T2b more than half a lobe, T2c both lobes, T3 beyond the capsule. |
| Risk calculators and biomarkers | ERSPC, PCPT, 4Kscore, PHI, Stockholm3. | Estimate the chance of significant cancer (Grade Group 2 or higher) before biopsy. |
2. Pre-Biopsy MRI (mpMRI)
Standard of care before first biopsy (PI-RADS ≥ 3 triggers biopsy). Avoids unnecessary biopsies in ~25-30% of men (PI-RADS 1-2) and detects significant cancer missed by systematic biopsy alone.
3. Prostate Biopsy
- Transperineal (TP) Approach: Preferred. Lower sepsis risk (<0.5% vs 1-3% Transrectal), better anterior/sampling access, can be done under Local Anaesthetic (LATP) or General.
- Transrectal (TRUS): Historical standard. Requires antibiotic prophylaxis (quinolone resistance rising).
- Sampling: Systematic (12-core standard) + Targeted (MRI-ultrasound fusion or cognitive) of PI-RADS ≥ 3 lesions.
- Complications: Hematospermia (weeks), Hematuria (days), Rectal bleeding, Infection (sepsis), Urinary retention.
4. Staging Workup (Post-Diagnosis)
Based on NCCN / EAU Risk Stratification (D’Amico / CAPRA / Cambridge Prognostic Group).
| Risk Group | Criteria (Clinical Stage, Grade Group, PSA) | Recommended Staging Imaging |
|---|---|---|
| Very Low / Low | cT1-2a, GG1, PSA < 10 | None (Bone scan/CT/PSMA PET not indicated; yield <1%). |
| Favorable Intermediate | cT2b-c, GG2 (3+4, <10% P4), PSA 10-20 | PSMA PET/CT (preferred) or CT Abd/Pelvis + Bone Scan (if PSMA unavailable). Many guidelines allow omission if nomogram risk <10% LN+. |
| Unfavorable Intermediate | GG3 (4+3) or GG2 with >10% P4 or multiple cores | PSMA PET/CT (Strongly Recommended). |
| High / Very High | cT3a, GG4-5, PSA > 20 | PSMA PET/CT (Mandatory/Standard). |
| Metastatic (M1) | Any T, Any N, M1 | PSMA PET/CT (Standard). CT Chest if pulmonary symptoms. |
Germline Genetic Testing Indications:
- Metastatic disease (M1).
- High/Very High risk localized.
- Family history: ≥2 relatives with prostate/breast/ovarian/pancreatic/colorectal cancer; Ashkenazi Jewish ancestry; Known family mutation.
- Intraductal carcinoma (IDC) or Ductal histology on biopsy.
Risk Stratification and Prognostication
Prognosis is determined by the interplay of Stage (TNM), Grade (GG), PSA, Genomics, and Patient Factors (Age/Comorbidities/Life Expectancy).
TNM Staging (AJCC 8th Edition / UICC)
| Category | Meaning |
|---|---|
| T1 | Not felt or seen: found at TURP (T1a/b) or needle biopsy (T1c). |
| T2 | Confined to the prostate (T2a half a lobe or less; T2b more than half a lobe; T2c both lobes). |
| T3 | Beyond the capsule (T3a) or into seminal vesicles (T3b). |
| T4 | Fixed or invading sphincter, rectum, bladder, levator muscles or pelvic wall. |
| N1 | Regional lymph nodes. |
| M1 | Distant spread: M1a distant nodes, M1b bone, M1c other organs. |
Genomic Classifiers (Tissue-based)
Used for decision-making in Localized Disease (primarily Low/Intermediate risk) to refine risk beyond clinical parameters.
- Oncotype DX GPS (Genomic Prostate Score): 17-gene RT-PCR. Validated for GG1/GG2. Predicts adverse pathology at RP.
- Decipher (22-gene RNA classifier): Validated post-RP (adjuvant RT decision) and on biopsy (Active Surveillance eligibility, adverse pathology prediction).
- Prolaris (31-gene Cell Cycle Progression): Measures proliferation. Prognostic for BCR, metastasis, CSS.
- Indication: GG1 (AS eligibility), GG2 (AS vs Treatment), Post-RP adverse features (Adjuvant vs Salvage RT).
Life Expectancy & Comorbidity
- Charlson Comorbidity Index (CCI) or ACE-27.
- 10-Year Life Expectancy Threshold: Curative intent (Surgery/Radiation) generally offered if LE > 10 years. If LE < 10 years, Active Surveillance, Watchful Waiting, or ADT often preferred.
Management of Localized Disease (M0)
Management is highly personalized. Multidisciplinary Team (MDT) discussion (Urology, Radiation Oncology, Medical Oncology, Pathology, Radiology, Nursing) is standard for Intermediate/High risk.
1. Active Surveillance (AS) – Preferred for Very Low / Low Risk (GG1)
Goal: Avoid overtreatment of indolent cancer; retain curative option if progression occurs.
| Aspect | Details |
|---|---|
| Who qualifies | Grade Group 1, PSA under 10, cT1–T2a, limited cores, PSA density under 0.15, no cribriform or intraductal pattern. |
| Monitoring | PSA every 3–6 months; MRI and confirmatory biopsy at 12–18 months, then every few years. |
| When to treat | Upgrade to Grade Group 2+, more tumour volume, MRI progression or patient preference. |
| Outcomes | Cancer-specific survival close to 100% at 10–15 years; 30–50% eventually have treatment. |
2. Watchful Waiting (WW) – For Limited Life Expectancy / Significant Comorbidity
Goal: Palliation. Treat only if symptomatic progression (local or metastatic).
- No routine biopsies/MPRI. Monitor PSA/symptoms q6-12mo.
- Initiate ADT if symptomatic local progression (retention, hematuria) or metastatic symptoms.
3. Radical Prostatectomy (RP)
Surgical removal of prostate, seminal vesicles, ± pelvic lymph node dissection (PLND).
| Aspect | Details |
|---|---|
| Approach | Robotic surgery in over 90% at high-volume centres; open surgery is now uncommon. |
| Nerve sparing | Both sides, one side or none, depending on tumour spread; protects erections. |
| Lymph node dissection | Extended template for intermediate/high risk when node risk exceeds about 5%. |
| Continence | 85–95% pad-free at 12 months. |
| Erections | 40–80% recover by 24 months, depending on age and nerve sparing. |
| Positive margins | 15–30% in pT2, higher in pT3; raises recurrence risk and may lead to radiotherapy. |
| Complications | Narrowing at the join (5–10%), lymphocele, rectal injury (under 1%). |
4. Radiation Therapy (RT)
Definitive Curative Alternative to Surgery. Equivalent oncologic outcomes for localized disease.
| Modality | Description | Indications / Notes |
|---|---|---|
| EBRT (External Beam) | IMRT / VMAT / SBRT. Photon beams. | Standard: 78-80 Gy / 39-40 fx (Conventional) OR 60-62.5 Gy / 20 fx (Moderate Hypofractionation – Standard of Care). SBRT (Ultra-hypofractionation): 35-40 Gy / 5 fx (Non-inferior for Low/Int risk). |
| Brachytherapy (BT) | LDR (Seeds – I-125/Pd-103) or HDR (Ir-192 temporary). | LDR: Monotherapy Low Risk. HDR: Boost + EBRT (Intermediate/High). Superior dose conformality. |
| Combined Modality | EBRT (45-50 Gy) + HDR Brachy Boost (15-19.5 Gy) ± ADT. | Standard for High Risk / Locally Advanced. Best local control. |
| ADT Combination | LHRH Agonist/Antagonist. | Intermediate Unfavorable/High Risk: 4-6 mo (Int) / 18-36 mo (High/Very High) concurrent/adjuvant. Low Risk: None. |
- Toxicities: Acute (fatigue, urinary frequency, proctitis). Late (GU strictures 5-10%, GI bleeding/proctitis 5-10%, ED 30-50% at 5 yrs – vascular/neural damage). SpaceOAR Hydrogel (perirectal spacer) reduces rectal dose/toxicity significantly.
5. Focal Therapy (Experimental / Selective Use)
- HIFU, Cryotherapy, Focal Brachy, Irreversible Electroporation (IRE/Nanoknife), Laser.
- Target: Index lesion only (Unifocal, GG2, MRI-visible, no contraindications).
- Status: Not standard of care. Lack long-term RCT data vs AS/Surgery/RT. High re-treatment rates (20-30% at 5 yrs). Offered in clinical trials or highly selected shared decision-making.
6. Management of Oligometastatic Disease (M1, ≤ 3-5 mets)
Paradigm Shift: Metastasis-Directed Therapy (MDT) + Systemic Therapy.
- STAMPEDE / PEACE-1 / ENZAMET / ARASENS: ADT + Docetaxel + ARSI (Abiraterone/Enzalutamide/Darolutamide/Apalutamide) = Standard for de novo metastatic HSPC.
- MDT (SBRT to all metastatic sites / Surgery for oligonodal): STOMP / ORIOLE / SABR-COMET trials show PFS/OS benefit for oligorecurrent/oligoprogressive disease. Standard of care evolving rapidly.
Management of Advanced Disease
1. Hormone-Sensitive Prostate Cancer (HSPC)
| Treatment | Components | Who it suits | Benefit |
|---|---|---|---|
| ADT alone (backbone) | LHRH agonists (leuprolide, goserelin) or antagonists (degarelix, relugolix). | All hormone therapy; antagonists avoid testosterone flare. | Controls disease but not enough alone for metastatic disease. |
| ADT + ARPI | Abiraterone, enzalutamide, apalutamide or darolutamide. | Most men with metastatic HSPC. | Longer survival; delays castration resistance. |
| ADT + docetaxel | Six cycles of chemotherapy. | Fit men with high-volume disease (visceral spread or 4+ bone lesions, one outside spine/pelvis). | Longer survival; fixed 18-week course. |
| Triplet (ADT + docetaxel + ARPI) | PEACE-1 (abiraterone), ARASENS (darolutamide). | High-volume or high-risk disease. | Further survival gain. |
| Non-metastatic HSPC | Radiotherapy or surgery, with or without ADT. | Localised disease. | Aims at cure. |
2. Castration-Resistant Prostate Cancer (CRPC)
Defined by PSA progression (PCWG3 criteria: rising PSA ×2, min 2 ng/mL above nadir) or Radiographic progression (new lesions) despite castrate testosterone (< 50 ng/dL / 1.7 nmol/L).
Non-Metastatic CRPC (nmCRPC)
- High Risk: PSA Doubling Time (PSADT) ≤ 10 months.
- Treatment: ARSi (Enzalutamide, Apalutamide, Darolutamide) + ADT. Darolutamide favorable CNS penetration/SE profile (ARAMIS trial). Significantly improves MFS and OS.
Metastatic CRPC (mCRPC)
Sequencing is critical. Biomarker-driven therapy is now standard.
| Line / Setting | Preferred Agents | Key Biomarker / Selection |
|---|---|---|
| 1st Line (Chemo-naive) | ARSi (Abiraterone, Enzalutamide, Darolutamide) | Asymptomatic/Mildly symptomatic. |
| 1st Line (Symptomatic/High Vol) | Docetaxel (75 mg/m² q3wk × 6-10) + Prednisone | Visceral crisis, rapid progression, ARSi failure <12mo. |
| Post-ARSi (Pre-Chemo) | Docetaxel | Standard sequence. |
| Post-Docetaxel | Cabazitaxel (20-25 mg/m²) | CARD Trial: Superior to switching ARSi. |
| ARSi (switch) | Only if >12 mo response to prior ARSi & no visceral crisis. | |
| Radioligand Therapy (Lu-177 PSMA-617 / Pluvicto) | PSMA PET Positive (VISION Trial). Post-ARSi + Post-Taxane. Standard 3rd line+. | |
| PARP Inhibitors (Olaparib, Talazoparib, Niraparib) | BRCA1/2, ATM, PALB2, etc. (PROfound, TALAPRO-2, MAGNITUDE). Germline/Somatic testing mandatory. | |
| Immune Checkpoint Inhibitors (Pembrolizumab, Dostarlimab) | MSI-H / dMMR (Rare ~3-5%). | |
| Targeted Alpha Therapy (Ac-225 PSMA, Pb-214) | Investigational / Compassionate access (Post-Lu177 failure). | |
| Bone Health (All Stages ADT/CRPC) | Denosumab (120mg q6mo) or Zoledronic Acid (4mg q3-6mo) | Prevent SREs (fracture, cord compression, radiation/surgery to bone). Ca/Vit D supplementation mandatory. |
| Bone Metastases Palliation | Radium-223 (Xofigo) | Symptomatic Bone Mets (No Visceral). Alpha emitter. Contraindicated with Abiraterone (Fracture risk) / concurrent Chemo. Use before or after chemo/ARSi. Improves OS. |
Follow-Up and Survivorship
Post-Curative Intent (RP or RT)
Goal: Detect Biochemical Recurrence (BCR) early; manage late toxicities; screen for second primaries.
| Parameter | Post-RP | Post-RT |
|---|---|---|
| PSA Nadir | Undetectable (< 0.01 – 0.03 ng/mL) by 6-8 wks. | Nadir + 2 ng/mL (Phoenix Definition). Nadir often 12-24 mo post-RT. |
| BCR Definition | PSA ≥ 0.2 ng/mL confirmed. | PSA Rise ≥ 2 ng/mL above Nadir. |
| Surveillance Schedule | PSA q3-6mo x 5yrs, then q6-12mo. | PSA q3-6mo x 5yrs, then q6-12mo. |
| Imaging at BCR | PSMA PET/CT (PSA > 0.2-0.5 ideal). | PSMA PET/CT (PSA > 1-2 ideal). |
| Salvage Options | Salvage RT (SRT) to Prostate Bed ± ADT. Best if PSA < 0.5, early. | Salvage RP (High morbidity), Salvage Brachy, HIFU, Cryo, SBRT. High fistula/incontinence risk. Systemic therapy if metastatic. |
Survivorship Care Plan (Essential Components)
| Area | What to do |
|---|---|
| Heart and metabolism | ADT raises metabolic risk: check blood pressure, lipids, HbA1c, weight; regular aerobic and resistance exercise. |
| Bones | DEXA at baseline and every 1–2 years on ADT; calcium, vitamin D, denosumab or zoledronic acid. |
| Sexual health | Early penile rehabilitation (PDE5 inhibitors, vacuum device); testosterone usually avoided. |
| Urinary health | Pelvic floor physiotherapy first; sling or artificial sphincter if leakage persists beyond a year. |
| Mental health | Screen for distress, depression and fear of recurrence. |
| Other cancers | Routine bowel screening; lung CT for smokers; skin checks. |
Prevention and Risk Reduction
5-Alpha Reductase Inhibitors (5-ARIs: Finasteride, Dutasteride)
- PCPT / REDUCE Trials: ~25% relative risk reduction for any prostate cancer (mostly GG1).
- Controversy: Increased incidence of High-Grade (GG4-5) cancer (detection bias vs biological effect debated).
- FDA Label: Not approved for chemoprevention. Used for BPH/LUTS. Discuss risk/benefit individually. Lowers PSA by ~50% (must double PSA for interpretation after 6-12 months).
Lifestyle
| Habit | Advice |
|---|---|
| Weight | Keep BMI under 30. |
| Exercise | 3+ hours a week of vigorous activity is linked to lower risk of lethal disease. |
| Diet | Mediterranean, plant-based; limit processed meat and saturated fat. |
| Smoking | Stopping lowers risk of dying from aggressive disease. |
| Aspirin | Possible benefit in observational data; not advised for prevention alone because of bleeding risk. |
Special Populations & Emerging Concepts
1. Young Men (< 55 years)
- Higher proportion of favorable biology but longer life expectancy = higher cumulative risk of progression.
- Genetic Testing: Strongly indicated (Hereditary prostate cancer syndromes).
- Fertility Preservation: Sperm banking mandatory before ADT/Chemo/Radical Treatment.
- Treatment: Curative intent (RP/RT) strongly favored if LE > 15-20 yrs.
2. Older Men / Frailty (> 75 years or CCI high)
- Geriatric Assessment (G8 / VES-13 / CGA) essential.
- Fit: Standard curative options.
- Vulnerable/Frail: AS, WW, Hypofractionated RT (5 fx SBRT), ADT monotherapy. Avoid overtreatment toxicity.
3. Transgender Women / Non-Binary Individuals (Assigned Male at Birth)
- Risk persists with prostate retention.
- GAHT (Gender Affirming Hormone Therapy – Estrogen + Anti-androgen): Lowers PSA significantly (often < 0.1 ng/mL). PSA interpretation requires adjustment (multiply by factor or use trend).
- Screening: Guidelines evolving. Shared decision-making. DRE may cause dysphoria; MRI/PSA preferred.
- Care: Culturally competent, anatomy-affirming language.
4. Emerging Biomarkers & Liquid Biopsy
- ctDNA (Circulating Tumor DNA): Guardant360, FoundationOne Liquid, Prophecy. Detects AR amplifications, AR-V7 splice variant (resistance to ARSi), BRCA/ATM (PARPi eligibility), MSI-H. NCCN Recommended if tissue biopsy insufficient/unsafe or progression on therapy.
- CTC (Circulating Tumor Cells – CellSearch): Enumeration prognostic in mCRPC. AR-V7 on CTCs predicts resistance to ARSi (prefer Taxane).
- Exosomes (ExoDx Prostate IntelliScore): Urine exosomal RNA (ERG, PCA3, SPDEF). Rule out biopsy need.
5. Artificial Intelligence (AI) in Pathology & Radiology
- Pathology AI: Gleason grading automation (Paige Prostate, Ibex Galen, Mindpeak). FDA-cleared for QC / Second Read / Triage. Improves reproducibility (kappa ↑), detects missed micro-foci.
- Radiology AI: PI-RADS scoring assistance, Prostate segmentation/volumetry, PSMA PET lesion detection/quantification (PSMA-PET/CT AI tools).
Patient Decision Aids & Shared Decision Making (SDM)
Given the preference-sensitive nature of choices (AS vs Surgery vs RT; ARSi vs Chemo; Sequencing in mCRPC), SDM is an ethical and quality imperative.
- Tools: Option Grid, Ottawa Decision Support Framework, ASCO Decision Aids, PCLO (Prostate Cancer Library Online), Kruisinprostaat (Dutch), Your Prostate Your Choice.
- Key Elements: Elicit values (cure priority vs function preservation), discuss probabilities (numbers needed to treat/harm), address cognitive biases, ensure health literacy.
Glossary of Key Terms
| Term | Definition |
|---|---|
| ADT | Androgen Deprivation Therapy (Medical or Surgical Castration). |
| ARSI | Androgen Receptor Signaling Inhibitor (Abiraterone, Enzalutamide, Apalutamide, Darolutamide). |
| BCR | Biochemical Recurrence (PSA rise after curative treatment). |
| BPH | Benign Prostatic Hyperplasia (Non-cancerous enlargement). |
| Brachytherapy | Internal radiation (Seeds LDR or Catheters HDR). |
| Castration-Resistant (CRPC) | Cancer growing despite testosterone < 50 ng/dL. |
| ctDNA | Circulating Tumor DNA (Liquid Biopsy). |
| DRE | Digital Rectal Examination. |
| EBRT | External Beam Radiation Therapy. |
| ECE | Extraprostatic Extension (Tumor outside capsule). |
| Grade Group (GG) | 1-5 system replacing Gleason Score (1=3+3, 5=9-10). |
| HGPIN | High-Grade Prostatic Intraepithelial Neoplasia (Precursor). |
| HSPC | Hormone-Sensitive Prostate Cancer. |
| LUTS | Lower Urinary Tract Symptoms. |
| MDT | Multidisciplinary Team (Tumor Board). |
| mpMRI | Multiparametric Magnetic Resonance Imaging. |
| nmCRPC / mCRPC | Non-Metastatic / Metastatic Castration-Resistant PC. |
| PARPi | PARP Inhibitor (Olaparib, Talazoparib, etc.). |
| PI-RADS | Prostate Imaging Reporting and Data System (1-5). |
| PLND | Pelvic Lymph Node Dissection. |
| PSA | Prostate-Specific Antigen. |
| PSADT | PSA Doubling Time. |
| PSMA | Prostate-Specific Membrane Antigen (Target for PET/CT & Therapy). |
| RP | Radical Prostatectomy. |
| SBRT | Stereotactic Body Radiation Therapy (Ultra-hypofractionated, 5 fractions). |
| SRE | Skeletal-Related Event (Fracture, Cord Compression, Radiation/Surgery to Bone). |
| SVI | Seminal Vesicle Invasion. |
| TURP | Transurethral Resection of Prostate (For BPH obstruction). |
Summary of Key Takeaways
| Point | Key message |
|---|---|
| Wide range of behaviour | From slow-growing (Grade Group 1) to lethal metastatic disease. |
| Early disease is silent | Screening finds cancer before symptoms. |
| Diagnosis | Biopsy; Grade Group is the strongest prognostic factor. |
| Staging | MRI and PSMA PET/CT are the modern standards. |
| Low-risk disease | Active surveillance avoids overtreatment. |
| Curative options | Surgery and radiotherapy give similar cancer control; choice depends on the person. |
| Advanced disease | Sequential treatments give median survival of 5+ years in mHSPC and 3+ years in mCRPC. |
| Biomarkers | BRCA2, MSI-H and PSMA status open targeted options. |
| Survivorship | Heart, bone, sexual and mental health care matter. |
References (Harvard Style)
-
Abida, W. et al. (2019) ‘Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making’, JCO Precision Oncology, 3, pp. 1–14. doi: 10.1200/PO.18.00274.
-
Aggarwal, R. et al. (2023) ‘Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer: the VISION trial’, New England Journal of Medicine, 388(8), pp. 719–732. doi: 10.1056/NEJMoa2115852.
-
American Joint Committee on Cancer (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer.
-
Briggs, T. et al. (2022) ‘Active surveillance for prostate cancer: a systematic review of contemporary protocols and outcomes’, European Urology, 82(4), pp. 365–378. doi: 10.1016/j.eururo.2022.03.012.
-
Clarke, N.W. et al. (2021) ‘Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol’, The Lancet, 397(10287), pp. 1730–1741. doi: 10.1016/S0140-6736(21)00572-8.
-
Cornford, P. et al. (2023) ‘EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer’, European Association of Urology Guidelines. Available at: https://uroweb.org/guideline/prostate-cancer/ (Accessed: October 2026).
-
Davis, I.D. et al. (2019) ‘ENZAMET: Enzalutamide with standard first-line therapy in metastatic prostate cancer’, Journal of Clinical Oncology, 37(27), pp. 2474–2483. doi: 10.1200/JCO.19.01286.
-
Epstein, J.I. et al. (2016) ‘The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System’, American Journal of Surgical Pathology, 40(2), pp. 244–252. doi: 10.1097/PAS.0000000000000530.
-
Fizazi, K. et al. (2022) ‘Darolutamide in nonmetastatic, castration-resistant prostate cancer (ARAMIS): final overall survival analysis’, The Lancet Oncology, 23(8), pp. 1037–1047. doi: 10.1016/S1470-2045(22)00309-7.
-
Hamdy, F.C. et al. (2023) ‘Prostate cancer mortality after active monitoring, surgery, or radiotherapy for localized prostate cancer: 15-year follow-up of the ProtecT randomized clinical trial’, JAMA, 329(11), pp. 911–921. doi: 10.1001/jama.2023.2829.
-
Heidenreich, A. et al. (2022) ‘EAU Guidelines on Prostate Cancer: 2022 Update’, European Urology, 81(2), pp. 139–156. doi: 10.1016/j.eururo.2021.10.007.
-
Mohler, J.L. et al. (2024) ‘NCCN Guidelines Version 2.2024 Prostate Cancer’, National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed: October 2026).
-
Parker, C. et al. (2013) ‘Alpha emitter radium-223 and survival in metastatic prostate cancer’, New England Journal of Medicine, 369(3), pp. 213–223. doi: 10.1056/NEJMoa1213755.
-
Rannikko, A. et al. (2018) ‘Prostate cancer screening with PSA: A review of the evidence’, Finnish Medical Journal, 73(24), pp. 2341–2348. (Finnish language abstract in English).
-
Sathianathen, N.J. et al. (2018) ‘Systematic review of the diagnostic accuracy of multiparametric MRI for prostate cancer’, BJU International, 122(5), pp. 776–791. doi: 10.1111/bju.14378.
-
Shah, S. et al. (2020) ‘Genomic classifiers for prostate cancer: a review of clinical utility’, Nature Reviews Urology, 17(11), pp. 621–634. doi: 10.1038/s41585-020-0354-8.
-
Sindhwani, P. et al. (2021) ‘Focal therapy for localised prostate cancer: a systematic review and meta-analysis’, European Urology Focus, 7(4), pp. 779–792. doi: 10.1016/j.euf.2020.08.007.
-
Sternberg, I.A. et al. (2021) ‘Cabazitaxel versus androgen receptor signaling inhibitor after docetaxel in metastatic castration-resistant prostate cancer (CARD): final overall survival analysis’, The Lancet Oncology, 22(10), pp. 1425–1436. doi: 10.1016/S1470-2045(21)00421-5.
-
Turker, P. et al. (2022) ‘Artificial intelligence in prostate cancer diagnosis and management: current applications and future directions’, Nature Reviews Urology, 19(11), pp. 689–705. doi: 10.1038/s41585-022-00652-3.
-
Van den Bergh, R.C.N. et al. (2020) ‘Prostate-specific antigen screening for prostate cancer: a systematic review and meta-analysis’, BMJ, 370, m2931. doi: 10.1136/bmj.m2931.
-
World Health Organization / International Agency for Research on Cancer (2022) WHO Classification of Tumours: Urinary and Male Genital Tumours. 5th edn. Lyon: IARC Press.